CN115400133B - Application of begonin in preparation of medicines for treating cardiac hypertrophy - Google Patents
Application of begonin in preparation of medicines for treating cardiac hypertrophy Download PDFInfo
- Publication number
- CN115400133B CN115400133B CN202211069071.8A CN202211069071A CN115400133B CN 115400133 B CN115400133 B CN 115400133B CN 202211069071 A CN202211069071 A CN 202211069071A CN 115400133 B CN115400133 B CN 115400133B
- Authority
- CN
- China
- Prior art keywords
- angiotensin
- group
- vitro
- heart
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010007572 Cardiac hypertrophy Diseases 0.000 title claims abstract description 29
- 208000006029 Cardiomegaly Diseases 0.000 title claims abstract description 16
- 239000003814 drug Substances 0.000 title claims abstract description 14
- 238000002360 preparation method Methods 0.000 title abstract description 10
- 229940079593 drug Drugs 0.000 title description 5
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 claims abstract description 55
- 102000005862 Angiotensin II Human genes 0.000 claims abstract description 52
- 101800000733 Angiotensin-2 Proteins 0.000 claims abstract description 52
- 229950006323 angiotensin ii Drugs 0.000 claims abstract description 52
- 238000001514 detection method Methods 0.000 claims abstract description 11
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 claims abstract description 5
- 238000000338 in vitro Methods 0.000 claims description 30
- 241000218993 Begonia Species 0.000 claims description 27
- 241000699670 Mus sp. Species 0.000 claims description 23
- 238000002474 experimental method Methods 0.000 claims description 21
- -1 angiotensin II compound Chemical class 0.000 claims description 20
- 238000003753 real-time PCR Methods 0.000 claims description 19
- 241000699666 Mus <mouse, genus> Species 0.000 claims description 13
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 claims description 10
- 230000002107 myocardial effect Effects 0.000 claims description 10
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 9
- 239000002609 medium Substances 0.000 claims description 9
- 230000003204 osmotic effect Effects 0.000 claims description 9
- 241001465754 Metazoa Species 0.000 claims description 8
- 210000005003 heart tissue Anatomy 0.000 claims description 7
- 239000012894 fetal calf serum Substances 0.000 claims description 6
- 238000010166 immunofluorescence Methods 0.000 claims description 4
- 238000003125 immunofluorescent labeling Methods 0.000 claims description 4
- 238000012339 Real-time fluorescence quantitative polymerase chain reaction Methods 0.000 claims description 3
- 241000208365 Celastraceae Species 0.000 claims description 2
- 241001528578 Malus halliana Species 0.000 claims description 2
- DFBIRQPKNDILPW-CIVMWXNOSA-N Triptolide Chemical compound O=C1OCC([C@@H]2C3)=C1CC[C@]2(C)[C@]12O[C@H]1[C@@H]1O[C@]1(C(C)C)[C@@H](O)[C@]21[C@H]3O1 DFBIRQPKNDILPW-CIVMWXNOSA-N 0.000 claims description 2
- 235000015140 cultured milk Nutrition 0.000 claims description 2
- 238000013227 male C57BL/6J mice Methods 0.000 claims description 2
- 239000002504 physiological saline solution Substances 0.000 claims description 2
- YKUJZZHGTWVWHA-UHFFFAOYSA-N triptolide Natural products COC12CC3OC3(C(C)C)C(O)C14OC4CC5C6=C(CCC25C)C(=O)OC6 YKUJZZHGTWVWHA-UHFFFAOYSA-N 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 26
- 101800000407 Brain natriuretic peptide 32 Proteins 0.000 description 19
- HPNRHPKXQZSDFX-OAQDCNSJSA-N nesiritide Chemical compound C([C@H]1C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1N=CNC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 HPNRHPKXQZSDFX-OAQDCNSJSA-N 0.000 description 19
- 102000002723 Atrial Natriuretic Factor Human genes 0.000 description 18
- 101800001288 Atrial natriuretic factor Proteins 0.000 description 18
- 101800001890 Atrial natriuretic peptide Proteins 0.000 description 18
- 102400000667 Brain natriuretic peptide 32 Human genes 0.000 description 18
- 101800002247 Brain natriuretic peptide 45 Proteins 0.000 description 18
- NSQLIUXCMFBZME-MPVJKSABSA-N carperitide Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 NSQLIUXCMFBZME-MPVJKSABSA-N 0.000 description 18
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 13
- 238000006243 chemical reaction Methods 0.000 description 13
- 208000024172 Cardiovascular disease Diseases 0.000 description 11
- 239000008055 phosphate buffer solution Substances 0.000 description 11
- 108010051583 Ventricular Myosins Proteins 0.000 description 10
- 238000010839 reverse transcription Methods 0.000 description 10
- 210000004413 cardiac myocyte Anatomy 0.000 description 9
- 108020004999 messenger RNA Proteins 0.000 description 8
- 230000000747 cardiac effect Effects 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 238000005406 washing Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 230000017531 blood circulation Effects 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 210000004115 mitral valve Anatomy 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 230000002861 ventricular Effects 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 206010020880 Hypertrophy Diseases 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 102000006382 Ribonucleases Human genes 0.000 description 4
- 108010083644 Ribonucleases Proteins 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 229930040373 Paraformaldehyde Natural products 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 230000003205 diastolic effect Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 229920002866 paraformaldehyde Polymers 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 238000007789 sealing Methods 0.000 description 3
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 2
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 2
- 102000015427 Angiotensins Human genes 0.000 description 2
- 108010064733 Angiotensins Proteins 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 208000006313 Delayed Hypersensitivity Diseases 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 102100028255 Renin Human genes 0.000 description 2
- 108090000783 Renin Proteins 0.000 description 2
- 229960002478 aldosterone Drugs 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000001969 hypertrophic effect Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
- 208000002330 Congenital Heart Defects Diseases 0.000 description 1
- 206010052337 Diastolic dysfunction Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 208000010159 IgA glomerulonephritis Diseases 0.000 description 1
- 206010021263 IgA nephropathy Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- 206010023421 Kidney fibrosis Diseases 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 206010042434 Sudden death Diseases 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 102000001307 androgen receptors Human genes 0.000 description 1
- 108010080146 androgen receptors Proteins 0.000 description 1
- 230000002280 anti-androgenic effect Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000001746 atrial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000005388 borosilicate glass Substances 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 230000036996 cardiovascular health Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 208000028831 congenital heart disease Diseases 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 208000026758 coronary atherosclerosis Diseases 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 208000018578 heart valve disease Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000036454 renin-angiotensin system Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 210000002235 sarcomere Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention discloses an application of begonin in preparation of a medicament for treating cardiac hypertrophy, belongs to the technical field of medicament preparation, and solves the problem of cardiac hypertrophy induced by angiotensin II in the prior art. The invention applies the begonine to the preparation of the medicament for treating the myocardial hypertrophy, and performs experimental contrast such as HE staining and heart M-type ultrasonic detection on the myocardial hypertrophy induced by the contrast angiotensin II, and can obviously reduce the myocardial hypertrophy induced by the angiotensin II after the begonine is treated.
Description
Technical Field
The invention belongs to the technical field of medicine preparation, and particularly relates to application of begoniin in preparation of medicines for treating cardiac hypertrophy.
Background
The prevalence rate of cardiovascular diseases in China is high, and the current state is still in a continuous rising stage, wherein the Chinese cardiovascular health and disease report 2021 indicates that: the incidence rate of cardiovascular diseases in China is high, about 3.30 hundred million people suffer from cardiovascular diseases, and the cardiovascular diseases in rural areas and cities in 2019 account for 46.74% and 44.26% of the causes of death respectively. At present, cardiovascular diseases are still the leading cause of death of residents in China, 2 cases of death patients in every 5 cases die from cardiovascular diseases, and economic burden brought by the cardiovascular diseases to China, society and families is gradually increased.
Various cardiovascular diseases such as long-term hypertension, valvular heart disease, congenital heart disease, coronary atherosclerosis heart disease and the like can finally lead to heart failure, and myocardial hypertrophy is a common pathological reaction in the development process of the diseases. Myocardial hypertrophy is characterized by hypertrophy of cardiac myocytes, hypertrophy of cardiac wall, excessive increase in ventricular size, and causes diastolic dysfunction, and due to an increase in the amount of oxygen consumed by the hypertrophic cardiac muscle, imbalance in supply and demand of myocardial oxygen further induces arrhythmia, myocardial infarction, sudden death, and the like, and is therefore considered as a predictor of the incidence and mortality of cardiovascular diseases. Myocardial hypertrophy occurs in early stages of cardiovascular diseases, and can be reversed to a certain extent after pathogenic factors are eliminated. Therefore, inhibiting and torquing the occurrence of myocardial hypertrophy is critical for reducing the incidence of cardiovascular disease and mortality.
The cardiac hypertrophy is characterized by the re-expression of fetal genes such as myocardial cell enlargement, sarcomere structure separation, enhanced protein synthesis, atrial Li Na peptide (Atrial natriuretic factor, ANP), brain natriuretic peptide (Brain natriuretic factor, BNP), beta-myosin heavy chain (beta-myosin heavy chain, beta-MHC), etc. Activation of the renin-angiotensin-aldosterone system (renin angiotension aldosterone system, RAAS) is one of the initiating and critical steps in the development of pathological myocardial hypertrophy among the numerous contributors to myocardial hypertrophy. The body activates RASS for a long time, which leads to a state of hypertension, and the produced renin, angiotensin and aldosterone cause myocardial cell hypertrophy, leading to heart reconstruction. Angiotensin II is one of the most important humoral factors of the RAAS system. Angiotensin II directly activates inflammatory responses in the heart and can regulate elevation of arterial blood pressure through vasoconstriction and sodium water retention. These effects can lead to pathological cardiac hypertrophy. How to effectively solve the cardiac hypertrophy induced by angiotensin II has become the current urgent problem to be solved.
At present, the pharmacological activity of the begonia extract is not studied much. Researches in the 90 th year Yang Jun of the last century show that begonin can inhibit delayed hypersensitivity of mice induced by babin oil and dimethylbenzene, reduce delayed hypersensitivity of mice caused by calf serum albumin, reduce IgG content in serum of the mice, and improve complement content in circulation of the mice. Recently, song Xianmei and the like have found that begonin can protect the kidney function of IgA nephropathy rats, alleviate renal interstitial fibrosis and improve Thl cell/Th 2 cell imbalance. Yang et al report that begonin has anti-androgenic activity and reduces androgen receptor expression. However, no report exists that begonia can reduce the induction of myocardial hypertrophy by angiotensin II. Therefore, the begonia extract is effectively applied to the preparation of the medicines for treating the myocardial hypertrophy.
Disclosure of Invention
The invention aims at overcoming the defects of the prior art and provides an application of begonia extract in preparing medicines for effectively relieving myocardial hypertrophy induced by angiotensin II.
In order to achieve the technical aim, the application of the begoniin in the preparation of the medicine for treating the cardiac hypertrophy adopts the following technical scheme:
the use of begonin in preparing medicine for treating cardiac hypertrophy comprises applying begonin in animal experiment and in vitro cell experiment;
the animal experiment comprises three experimental groups which are divided into a control group, an angiotensin II group and an angiotensin II compound begoniin group, wherein the control group is subcutaneously implanted with a micro osmotic pump filled with physiological saline for 4 weeks, the angiotensin II group is subcutaneously implanted with a micro osmotic pump filled with angiotensin II with the dosage of 1.46mg/kg/d for 4 weeks, the angiotensin II compound begoniin group is subcutaneously implanted with a micro osmotic pump filled with angiotensin II with the dosage of 1.46mg/kg/d for 4 weeks, and simultaneously, the heart M ultrasonic detection is carried out after 4 weeks, and heart tissue is left;
the in vitro cell experiment comprises three experimental groups, namely an in vitro control group, an in vitro angiotensin II group and an in vitro angiotensin II compound begonia extract group, wherein the in vitro control group cultures cells for 48 hours in a DMEM (DMEM) medium containing 10% fetal calf serum, the in vitro angiotensin II group cultures stem pre-cells for 48 hours in the DMEM medium containing 10% fetal calf serum and 4umol/L angiotensin II, and the in vitro angiotensin II compound begonia extract group carries out real-time fluorescence quantitative polymerase chain reaction (q-PCR), immunofluorescence and the like on the cells after the DMEM medium containing 10% fetal calf serum, 4umol/L angiotensin II and 100ug/L begonia extract intervenes in the cells for 48 hours.
Preferably, the animal experiments and in vitro cell experiments comprise HE staining, cardiac M-type ultrasonic detection, real-time fluorescent quantitative polymerase chain reaction (q-PCR) of cardiac tissue, cellular immunofluorescent staining and real-time fluorescent quantitative polymerase chain reaction (q-PCR) of myocardial cells.
Preferably, the experiments of the control group, the angiotensin II group and the angiotensin II compound begonia are carried out by adopting 8 mice in each group, wherein the mice are male C57BL/6J mice with the weight of 25-28 g and the age of 8 weeks. _cell
Preferably, the begonin is a triptolide, and is prepared by separating Malus halliana of Celastraceae.
Preferably, the begoniin has a molecular structural formula:。
compared with the prior art, the invention has the beneficial effects that:
according to the invention, the begonine is applied to the preparation of a medicament for treating cardiac hypertrophy, and compared with the cardiac hypertrophy induced by the angiotensin II, HE staining, cardiac M-type ultrasonic detection, cardiac tissue real-time fluorescent quantitative polymerase chain reaction, cell immunofluorescent staining and experimental comparison of cardiac myocyte real-time fluorescent quantitative polymerase chain reaction are carried out, so that the cardiac hypertrophy induced by the angiotensin II can be obviously reduced, the wall thickness before and after the heart in systole and the wall thickness before and after the heart in diastole are reduced, the peak velocity of mitral valve blood flow in early diastole/peak velocity of mitral valve blood flow in end diastole (E/A value) is increased, the mRNA content of cardiac Atrial Natriuretic Peptide (ANP), brain Natriuretic Peptide (BNP) and beta-myosin heavy chain (beta-MHC) is obviously reduced, and the mRNA content of Atrial Natriuretic Peptide (ANP), brain Natriuretic Peptide (BNP) and beta-myosin heavy chain (beta-MHC) is obviously reduced.
Drawings
FIG. 1 shows the results of hematoxylin-eosin (HE) staining of mice after modeling with angiotensin II and treatment with begoniin;
FIG. 2 shows the results of cardiac M-type ultrasound testing of mice for myocardial hypertrophy following angiotensin II modeling and treatment with begonia;
FIG. 3 shows the results of cardiac M-type ultrasound testing of mice diastolic function following angiotensin II modeling and treatment with begoniin;
FIG. 4 shows the results of real-time fluorescence quantitative polymerase chain reaction (q-PCR) studies on angiotensin II modeling and mRNA levels of mouse cardiac Atrial Natriuretic Peptide (ANP), brain Natriuretic Peptide (BNP), and beta-myosin heavy chain (beta-MHC) following treatment with begonin;
FIG. 5 shows the results of immunofluorescence assay for the effects of begoniin on angiotensin II-induced cardiomyocyte hypertrophy in vitro;
FIG. 6 is a result of real-time fluorescent quantitative polymerase chain reaction (q-PCR) method for studying the effect of begoniin on the in vitro angiotensin II-induced mRNA levels of cardiac myocytes, atrial Natriuretic Peptide (ANP), brain Natriuretic Peptide (BNP), and beta-myosin heavy chain (beta-MHC).
Detailed Description
The invention is further described below in conjunction with the specific embodiments:
the use of begonin in preparing medicine for treating cardiac hypertrophy comprises applying begonin in animal experiment and in vitro cell experiment;
the animal experiments comprise three groups of experiments which are divided into a control group, an angiotensin II group and an angiotensin II compound begonia extract, wherein the control group is subcutaneously implanted with a micro osmotic pump filled with normal saline for 4 weeks, the angiotensin II group is subcutaneously implanted with a micro osmotic pump filled with the angiotensin II with the dosage of 1.46mg/kg/d for 4 weeks, the angiotensin II compound begonia extract is subcutaneously implanted with the micro osmotic pump filled with the angiotensin II with the dosage of 1.46mg/kg/d for 4 weeks, and at the same time, the heart M type ultrasonic detection is carried out after 4 weeks by using the begonia extract with the dosage of 3mg/kg/d, and heart tissues are left, and the experiments of the control group, the angiotensin II group and the angiotensin II compound begonia extract are adopted, wherein each group adopts 8 mice, and the mice are male C57/6J mice with the body weights of 25-28 g and the ages of 8 weeks;
the in vitro cell experiment comprises three groups of experiments of dividing in vitro primary cultured milk mouse myocardial cells into an in vitro control group, an in vitro angiotensin II group and an in vitro angiotensin II compound begonia extract, wherein the in vitro control group cultures the cells for 48 hours in a DMEM medium containing 10% fetal bovine serum, the in vitro angiotensin II group pre-cultures the cells for 48 hours in a DMEM medium containing 10% fetal bovine serum and 4umol/L angiotensin II, and the in vitro angiotensin II compound begonia extract is used for q-PCR, immunofluorescence and other detection of the cells after the DMEM medium containing 10% fetal bovine serum, 4umol/L angiotensin II and 100ug/L begonia extract is used for intervening the cells for 48 hours.
Example 1, heart staining HE staining of mice
S1, taking out eyeballs, taking out blood, taking out the blood in a mouse body, taking out the heart of the mouse, washing in Phosphate Buffer Solution (PBS), gently squeezing the heart, and removing residual blood in the heart until the squeezed liquid in the heart is completely clear;
s2, taking out the heart from the PBS, thoroughly sucking the PBS, cutting the heart from the middle position in a horizontal plane, and putting the heart into 10% paraformaldehyde for fixation;
s3, taking out the heart of the mouse, cutting the heart at the middle position in a horizontal plane, putting the heart into 10% paraformaldehyde for fixation, embedding paraffin, slicing with 2 mu m, conventionally dewaxing to water before dyeing, staining the core with hematoxylin for 10min, washing with clean water for 3 times, differentiating with hydrochloric acid and alcohol for 1S, washing with clean water for 3 times, staining with eosin for 30S, and washing with clean water for 1 time. Airing, sealing and observing.
As shown in FIG. 1, after modeling by angiotensin II, the heart of mice is hypertrophic compared with the control group, while the heart hypertrophy degree of mice in the angiotensin II compound begonia group is obviously reduced compared with that of mice in the angiotensin II group.
Example 2, M-ultrasonic detection of mouse heart
S1, lightly anesthetizing a mouse by using 2% isoflurane/100% oxygen, lying the mouse on a heating plate, and measuring heart two-dimensional M-shaped ultrasonic by a parasternal long shaft;
s2, detecting the structure and the function of a mouse heart by adopting a noninvasive transthoracic high-resolution mouse heart ultrasonic imaging system, wherein the probe frequency is 30MHz;
the S3 detection index comprises: left ventricular end diastole anterior wall thickness, left ventricular end systole anterior wall thickness, left ventricular end diastole posterior wall thickness, left ventricular end systole posterior wall thickness, left ventricular end diastole early mitral valve blood flow peak velocity to end diastole mitral valve blood flow peak velocity ratio, and the like.
As seen from FIG. 2, after modeling with angiotensin II, the indices reflecting myocardial hypertrophy such as anterior and posterior wall thickness of the systolic heart, anterior and posterior wall thickness of the diastolic heart, etc. of the angiotensin II group mice were significantly increased compared to the control group, while the indices such as anterior and posterior wall thickness of the systolic heart, anterior and posterior wall thickness of the diastolic heart, etc. of the angiotensin II compound begonia group mice were significantly decreased compared to the angiotensin II group.
As seen in FIG. 3, after modeling with angiotensin II, peak velocity of mitral valve blood flow at early diastole/peak velocity of mitral valve blood flow at end diastole (E/A ratio) was significantly lower than that of the control group, and E/A ratio of mice with angiotensin II compound begonia group was increased than that of angiotensin II group.
Example 3 real-time fluorescent quantitative polymerase chain reaction (q-PCR) of mouse heart tissue
Extraction of RNA of myocardial tissue: s1, cutting a heart by a blade after sterilization for about 5mg, pre-cooling in liquid nitrogen for 5min, grinding in a high borosilicate glass grinder until no macroscopic tissue mass exists, adding a 1 mLTrilzol reagent, standing at room temperature for 5min, transferring the liquid into a 1.5mLEP tube, adding 200UL chloroform, vigorously shaking for 25S, and standing at room temperature for 3min.
S2, pre-cooling by a centrifugal machine in advance, centrifuging at a speed of 12000rpm for 15min in an environment of 4 ℃, wherein the liquid in the EP tube is visible to be divided into 3 layers, the colorless liquid on the upper layer is sucked, the upper layer is transferred to a new EP tube, and the equal volume of isopropanol is added and vibrated to be uniformly mixed.
S3, centrifuging at 12000rpm for 15min in a 4 ℃ environment, wherein RNA precipitation is visible at the bottom of the EP tube after centrifugation, removing supernatant, adding 1mL of 100% alcohol, washing, and centrifuging at 7500rpm for 5min again.
After S4RNA washing is finished, the water in the EP tube is sucked away, 20 mu L of DEPC water is added according to the amount of RNA to redissolve the RNA, an RNA concentration detector detects the concentration and purity of the RNA, and the ratio of OD260/280 is controlled to be 1.8-2.0.
Reverse Transcription (RT) reaction: reaction System (20 ul): 5 Xmix 4 mu L, total RNA 1000ng, RNase Free dH2O to make up the volume to 20uL, centrifuging in a palm centrifuge for 1min after sample addition, carrying out reverse transcription on a reverse transcription instrument after centrifugation, and storing cDNA after reverse transcription at-80 ℃ for standby after the reaction procedure from 37 ℃ 15min to 85 ℃ for 5s to 4 ℃ to the end.
Real-time fluorescent quantitative polymerase chain (RT-PCR) reaction: reaction System (10 ul): sybr 5. Mu.L, front primer 0.4. Mu.L, rear primer 0.4. Mu. L, DNA 1. Mu.L, RNase Free dH2O 3.2. Mu.L, after the sample was applied, the sealing film sealed the PCR test plate, the PCR test plate with the applied sample was centrifuged at a speed of 3000rpm at 4℃for 5min, and shaking was prevented, and q-PCR reaction was performed.
As seen in FIG. 4, after modeling with angiotensin II, the mRNA levels of Atrial Natriuretic Peptide (ANP), brain Natriuretic Peptide (BNP) and beta-myosin heavy chain (beta-MHC) were significantly increased in mice compared to the control group, and the mRNA levels of Atrial Natriuretic Peptide (ANP), brain Natriuretic Peptide (BNP) and beta-myosin heavy chain (beta-MHC) were decreased in the group of angiotensin II-complex begonia.
Example 4 immunofluorescent staining of the cells of the suckling mice
Sterile slides were pre-placed in 24 well plates and the breast rat cardiomyocytes were cultured in 24 well plates and were intervened for 48 hours. The cells were gently washed 3 times with 3min each, 4% paraformaldehyde for 15min, 3 times with PBS, 5min each, 0.2% Triton membrane rupture for 20min each, 3 times with PBS, 5min each, 3% BSA for 1 hour at room temperature, 3 times with PBS, 5min each, and overnight incubation of selected troponin primary antibody solution at 4℃with PBS for 3 times, 5min each. The corresponding secondary antibody solution was incubated at 37℃for 1 hour. The PBS was washed 3 times for 5 minutes each. DAPI nuclei were stained for 10min and washed with PBS. And (5) observing and photographing by a fluorescence microscope.
As seen in FIG. 5, compared with the control group, the volume of the myocardial cells of the angiotensin II group is obviously increased, and the volume of the myocardial cells of the angiotensin II compound begonia group is obviously reduced compared with the angiotensin II group.
Example 5 real-time fluorescent quantitative polymerase chain reaction (q-PCR) of mouse cardiomyocytes
Extraction of cardiomyocyte RNA: after S1 cell intervention was completed, the cells were washed once with PBS, 1mL of LTrilzol reagent was added to each well, left at room temperature for about 5 minutes, gently swirled and mixed, and the mixed solution was placed into a 1.5mL enzyme-free EP tube.
S2, adding 0.2mL of chloroform into each EP tube, vigorously shaking for 20S, carrying out ice bath for 10min, and after the ice bath is finished, moving into a 4-degree centrifugal machine, carrying out centrifugal treatment at 12000rpm for 15min, wherein the liquid in the EP tube can be seen to be divided into three layers.
S3 transfer the upper colorless aqueous phase to a 1.5ml EP tube with a pipette at 1:1, adding isopropanol in volume ratio, reversing, mixing, standing at room temperature for 10min, centrifuging at 12000rpm in a 4-degree centrifuge for 10min, removing supernatant after centrifuging, adding 1mL of 100% ethanol, shaking, washing, placing on ice for a short time, fully drying, adding 20ul of DEPC water, dissolving, mixing, and storing at-80 ℃ for standby.
S4, detecting the concentration and purity of the RNA by adopting an RNA concentration detector, wherein the concentration and purity of the RNA are detected by adopting the RNA concentration detector, and the ratio of OD260/280 is controlled to be 1.8-2.0.
Reverse Transcription (RT) reaction: reaction System (20 ul): 5 Xmix 4. Mu.L, total RNA 1000ng, RNase Free dH2O to 20uL, centrifuging in palm centrifuge for 1min after sample addition, and performing reverse transcription on a reverse transcription instrument after centrifugation, wherein the reaction procedure is from 37deg.C 15 min-85deg.C 5 s-4deg.C. The cDNA after the reverse transcription was stored at-80℃for use.
Real-time fluorescent quantitative polymerase chain (RT-PCR) reaction: reaction System (10 ul): sybr 5. Mu.L, front primer 0.4. Mu.L, rear primer 0.4. Mu. L, DNA 1. Mu.L, RNase Free dH2O 3.2. Mu.L, after the sample was applied, the sealing film sealed the PCR test plate, the PCR test plate with the applied sample was centrifuged at a speed of 3000rpm at 4℃for 5min, and shaking was prevented, and q-PCR reaction was performed.
As can be seen from FIG. 6, the content of Atrial Natriuretic Peptide (ANP), brain Natriuretic Peptide (BNP) and beta-myosin heavy chain (beta-MHC) mRNA in the cardiomyocytes of the angiotensin II group is obviously increased compared with that of the control group, and the content of Atrial Natriuretic Peptide (ANP), brain Natriuretic Peptide (BNP) and beta-myosin heavy chain (beta-MHC) mRNA in the cardiomyocytes of the angiotensin II compound begonia group is obviously reduced compared with that of the angiotensin II group.
In summary, the present invention is not limited to the preferred embodiments, but includes all equivalent changes and modifications in shape, construction, characteristics and spirit according to the scope of the claims.
Claims (4)
1. Use of begonin as sole active ingredient in the manufacture of a medicament for the treatment of a cardiac hypertrophy condition characterized in that: comprises the application of begoniin in animal experiments and in vitro cell experiments;
the animal experiment comprises three experimental groups which are divided into a control group, an angiotensin II group and an angiotensin II compound begoniin group, wherein the control group is subcutaneously implanted with a micro osmotic pump filled with physiological saline for 4 weeks, the angiotensin II group is subcutaneously implanted with a micro osmotic pump filled with angiotensin II with the dosage of 1.46mg/kg/d for 4 weeks, the angiotensin II compound begoniin group is subcutaneously implanted with a micro osmotic pump filled with angiotensin II with the dosage of 1.46mg/kg/d for 4 weeks, and at the same time, the begoniin is irrigated with the stomach with the dosage of 3mg/kg/d, and heart M type ultrasonic detection is carried out after 4 weeks, and heart tissues are left;
the in vitro cell experiment comprises three experimental groups of in vitro primary cultured milk mouse myocardial cells, namely an in vitro control group, an in vitro angiotensin II group and an in vitro angiotensin II compound begonia extract, wherein the in vitro control group cultures the cells for 48 hours in a DMEM (medium with 10% fetal calf serum), the in vitro angiotensin II group intervenes the cells for 48 hours in a DMEM (medium with 10% fetal calf serum and 4umol/L angiotensin II), and the in vitro angiotensin II compound begonia extract performs real-time fluorescence quantitative polymerase chain reaction and immunofluorescence detection on the cells after the DMEM (medium with 10% fetal calf serum, 4umol/L angiotensin II and 100ug/L begonia extract intervenes the cells for 48 hours;
the begonia extract has the structural formula:。
2. use according to claim 1, characterized in that: the animal experiment and the in-vitro cell experiment comprise HE staining, heart M-type ultrasonic detection, heart tissue real-time fluorescent quantitative polymerase chain reaction, cell immunofluorescent staining and myocardial cell real-time fluorescent quantitative polymerase chain reaction.
3. Use according to claim 1, characterized in that: the experiment of the control group, the angiotensin II group and the angiotensin II compound begonia element group adopts 8 mice in each group, and the mice are male C57BL/6J mice with the weight of 25-28 g and the age of 8 weeks.
4. Use according to claim 1, characterized in that: the begonin is triptolide, and is prepared by separating Malus halliana of Celastraceae.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211069071.8A CN115400133B (en) | 2022-09-01 | 2022-09-01 | Application of begonin in preparation of medicines for treating cardiac hypertrophy |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211069071.8A CN115400133B (en) | 2022-09-01 | 2022-09-01 | Application of begonin in preparation of medicines for treating cardiac hypertrophy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115400133A CN115400133A (en) | 2022-11-29 |
| CN115400133B true CN115400133B (en) | 2024-02-06 |
Family
ID=84163619
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211069071.8A Active CN115400133B (en) | 2022-09-01 | 2022-09-01 | Application of begonin in preparation of medicines for treating cardiac hypertrophy |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115400133B (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH11302171A (en) * | 1998-04-16 | 1999-11-02 | Mitsuhiro Hatta | Platelet-derived growth factor increase inhibitor and arteriosclerosis preventive/therapeutic agent |
| CN1276209A (en) * | 2000-05-26 | 2000-12-13 | 北京大学医学部 | Application of tripterygium plant extract in preventing and curing diseases in nervous system |
| WO2002017931A1 (en) * | 2000-09-01 | 2002-03-07 | Xiaomin Wang | Use of tripterygium wilfordii hook.f's extracts for preparation of medicaments for preventing and treating nervous system disorde rs |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7270835B2 (en) * | 2001-06-20 | 2007-09-18 | Metaproteomics, Llc | Compositions that treat or inhibit pathological conditions associated with inflammatory response |
-
2022
- 2022-09-01 CN CN202211069071.8A patent/CN115400133B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH11302171A (en) * | 1998-04-16 | 1999-11-02 | Mitsuhiro Hatta | Platelet-derived growth factor increase inhibitor and arteriosclerosis preventive/therapeutic agent |
| CN1276209A (en) * | 2000-05-26 | 2000-12-13 | 北京大学医学部 | Application of tripterygium plant extract in preventing and curing diseases in nervous system |
| WO2002017931A1 (en) * | 2000-09-01 | 2002-03-07 | Xiaomin Wang | Use of tripterygium wilfordii hook.f's extracts for preparation of medicaments for preventing and treating nervous system disorde rs |
Also Published As
| Publication number | Publication date |
|---|---|
| CN115400133A (en) | 2022-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021535894A (en) | Extracellular vesicles derived from mesenchymal stem cells | |
| CN105769916B (en) | Application of the source for mesenchymal stem cells excretion body in preparation treatment preeclampsia drug or preparation | |
| CN116904394A (en) | Preparation method and application of anti-inflammatory mesenchymal stem cell-derived exosome | |
| CN115400133B (en) | Application of begonin in preparation of medicines for treating cardiac hypertrophy | |
| CN109701023A (en) | It treats coronal young weak pulse embolism and causes myocardial damage drug and animal model constructing method | |
| CN112725266B (en) | Method for establishing simulation type valve interstitial cell calcification model | |
| US20200376037A1 (en) | Stem cell preparation resisting hypoxia injury, preparation method therefor, and use thereof in preparation of medicament for treating acute myocardial infarction | |
| CN116426469B (en) | Application of LAP2 alpha in mesenchymal stem cell adipogenic differentiation | |
| CN110292629B (en) | Application of hexokinase 1 in delaying senescence | |
| CN111870639A (en) | Application of Tibetan medicine scindapsus aureus in preparing medicine for treating atherosclerosis | |
| WO2023098088A1 (en) | Effect of exosome in thoracic aortic dissection/aneurysm | |
| CN1569884A (en) | Method for preparing astragaloside and its use in preparation of drug for preventing and treating diabetic nephropathy | |
| CN110511930B (en) | Sal-miR-58 and application thereof in inhibition of vascular inflammatory reaction and aneurysm formation | |
| CN102160866A (en) | Application of tanshinone IIA or pharmaceutically acceptable salts thereof in preparing medicines for treating or preventing pulmonary hypertension disease | |
| CN116617394A (en) | Application of histamine H2 receptor antagonist in preparation of medicines for treating myocardial fibrosis | |
| Tai et al. | CREG improves cardiac function by regulating cardiomyocytes’ autophagy in diabetic myocardial infarction rats. | |
| Chang et al. | Facilitation of ultrasonic microvesicles on homing and molecular mechanism of bone marrow mesenchymal stem cells in cerebral infarction patients. | |
| CN108379555A (en) | Applications of the FGF21 in the drug for preparing hypertension and/or angiosis damage that treatment is caused by angiotensinⅡ | |
| CN116555411A (en) | Application of LncRNA KCND1 in preparation of medicament for preventing and treating pathological myocardial hypertrophy | |
| RU2336528C2 (en) | Method of early postoperative complications prediction in patients with rheumatic heart diseases | |
| CN114010658B (en) | TREM2 hi Application of macrophage in preparing medicine for treating cardiac dysfunction | |
| CN113072634B (en) | Cell membrane transient receptor potential C6 channel immunogenic short peptide, vaccine thereof and pharmaceutical application of vaccine to resisting ventricular fibrosis | |
| CN114533726B (en) | Small molecule drug for inhibiting fibrosis and application thereof | |
| CN114058591B (en) | Recombinant mesenchymal stem cell and application thereof | |
| CN114560817B (en) | Small molecule drug for inhibiting fibrosis and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |